Every 10-Q that Grace Therapeutics, Inc. (GRCE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GRCE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRCE filings page.
Grace Therapeutics, Inc. reported a first-quarter net loss of $15.8M, sharply higher than a year earlier, driven mainly by a $13.5M impairment of in-process R&D for de-prioritized programs GTx-102 and GTx-101. Core operating expenses declined, with research and development at $0.7M and general and administrative at $1.7M.
The company is now concentrated on lead asset GTx-104, an IV nimodipine formulation for aneurysmal subarachnoid hemorrhage. After an April 2026 FDA Complete Response Letter focused on CMC and nonclinical items, Grace is pursuing a dual-source manufacturing strategy and preparing an NDA resubmission.
Cash and cash equivalents were $13.8M at June 30, 2026, supplemented by an August 2026 private placement yielding ~$9.1M, bringing cash to $22.2M. Management believes this funds planned operations, including CRL remediation, through at least the end of calendar 2028, though additional capital will be needed for ongoing operations beyond that horizon.
Grace Therapeutics reported a smaller net loss while advancing its lead drug GTx-104 toward potential approval. For the quarter ended December 31, 2025, net loss was $2.3 million, or $0.14 per share, improving from $4.2 million a year earlier, mainly as research and development spending declined. For the nine months, net loss narrowed to $6.6 million from $10.2 million. Cash and cash equivalents were $18.7 million and total assets $68.5 million, with minimal liabilities of $3.6 million, leaving stockholders’ equity at $64.9 million. The company completed a $13.7 million net private placement in February 2025 and raised an additional $4.0 million from warrant exercises. GTx-104’s New Drug Application was accepted by the FDA with an April 23, 2026 PDUFA date, following a Phase 3 trial that met its primary endpoint and supported an NDA under the 505(b)(2) pathway.
Grace Therapeutics, Inc. filed Amendment No. 1 to its quarterly report to correct the number of common shares reported as outstanding on the cover page. The amended filing now states that 15,474,026 shares of common stock were outstanding as of November 13, 2025. The company confirms that no other changes were made to the original quarterly report, and no financial statements were updated. In line with amendment rules, the company included new certifications from its chief executive officer and principal financial officer as exhibits.
Grace Therapeutics (GRCE) filed its quarterly report for the quarter ended September 30, 2025. The company reported a net loss of $0.9 million (basic and diluted loss per share of $0.06) for the quarter and a six‑month net loss of $4.3 million (loss per share of $0.27).
Cash and cash equivalents were $16.9 million as of September 30, 2025. Operating cash outflow totaled $4.9 million for the six months. Total liabilities were $3.8 million, with derivative warrant liabilities declining to $0.2 million from $1.1 million at March 31, 2025. Stockholders’ equity stood at $62.8 million. The company states existing cash is sufficient to sustain planned operations for at least 12 months from the statements’ issuance.
Development remains centered on GTx‑104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage: the NDA was accepted with a PDUFA target date of April 23, 2026. Subsequent to quarter end, Grace received $4.0 million in gross proceeds from 2023 warrant exercises. Shares outstanding were 14,128,562 as of November 13, 2025.
Grace Therapeutics (GRCE) is a clinical‑stage company focused on reformulated drugs for rare and orphan diseases. The company reports $20.0 million in cash and cash equivalents and 13,828,562 shares outstanding, and states its existing cash is expected to sustain operations for at least 12 months. The company completed a private placement that generated net proceeds of $13.7 million.
Grace submitted a New Drug Application for its lead candidate, GTx-104, an intravenous nimodipine formulation. Its pivotal Phase 3 STRIVE-ON trial met the primary safety endpoint versus oral nimodipine: a 19% reduction in patients experiencing clinically significant hypotension (28% vs 35%). Other reported advantages included higher dose intensity (54% ≥95% vs 8%), a 29% relative increase in favorable 90‑day modified Rankin outcomes, favorable pharmacoeconomic measures, and comparable adverse event rates. The trial arms had eight deaths on the GTx-104 arm vs four on oral nimodipine; the company reports no deaths were determined to be related to study drug.
For the quarter, net loss was $3.36 million (loss per share $0.21). Research and development spending fell following completion of the pivotal trial. The company carries derivative warrant liabilities whose fair‑value movements affected results and has multiple outstanding warrants that could dilute equity. Management notes additional financing will be required to advance other candidates.